Screener
Ligand Pharmaceuticals LGND Qarziba — Gross carrying value
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsGross.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 / Gross carrying value(1) | June 30, 2026 / Allowance | June 30, 2026 / Net carrying value (1) | December 31, 2025 / Gross carrying value(1) | December 31, 2025 / Allowance | December 31, 2025 / Net carrying value(1) |
|---|---|---|---|---|---|---|
| Qarziba | $101,303 | $(468) | $100,835 | $118,593 | $(498) | $118,095 |
| Agenus Bot/Bal | 40,815 | (408) | 40,407 | 40,815 | (408) | 40,407 |
| Tolerance Therapeutics (Tzield®) | 25,470 | (99) | 25,371 | 25,257 | (98) | 25,159 |
| Ohtuvayre inventors | 19,957 | (179) | 19,778 | 16,921 | (151) | 16,770 |
| Elutia (CorMatrix) | 6,062 | (837) | 5,225 | 6,607 | (1,107) | 5,500 |
| AT220 | 4,442 | (109) | 4,333 | 5,132 | (132) | 5,000 |
| Primrose mRNA | 3,281 | (98) | 3,183 | 3,281 | (98) | 3,183 |
| Zerion | 2,640 | (79) | 2,561 | — | — | — |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's qarziba — gross carrying value?
- Ligand Pharmaceuticals (LGND) reported qarziba — gross carrying value of $101.3M in Q2 2026.
- What does qarziba — gross carrying value mean?
- Reflects the initial cost or acquisition value of an intangible asset or royalty stream before accounting for accumulated amortization or impairment. It provides insight into the total capital investment allocated to the specific product line or intellectual property.
Ask your AI about Ligand Pharmaceuticals's qarziba — gross carrying value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude